exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088481 RNA Name: hsa-miR-4426 RNA Type: miRNA Chromosome: chr1 Starnd: + Coordinate: Start Site(bp): 192716333 End Site(bp): 192716349 External Links: hsa-miR-4426

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand UFC1 chr1 161152776 161158856 + NDUFA4 chr7 10931943 10940153 - N4BP3 chr5 178113532 178126081 + MTRNR2L11 chr1 237943724 237945275 - RNF181 chr2 85595725 85597708 + VMP1 chr17 59707192 59842255 + DDB1 chr11 61299451 61342596 - SAP18 chr13 21140514 21149084 + DOCK6 chr19 11199295 11262524 - NSMAF chr8 58583508 58659853 - APP chr21 25880550 26171128 - TMEM170A chr16 75443054 75465497 - TKFC chr11 61333210 61353295 + CTSZ chr20 58995185 59007254 - AL136454.1 chr1 192716132 192716653 + TPT1 chr13 45333471 45341370 - PTPN6 chr12 6946468 6961316 + CAPNS1 chr19 36139953 36150353 + CCNL2 chr1 1385711 1399335 - RABGAP1L chr1 174159410 174995308 + RACK1 chr5 181236897 181248096 - HMGN2 chr1 26472440 26476642 + SEZ6L2 chr16 29871159 29899547 - GAPDH chr12 6534512 6538374 + CD52 chr1 26317958 26320523 + PCBP2 chr12 53452102 53481162 + NDUFA11 chr19 5891276 5904006 - REXO1 chr19 1815248 1848483 - ZNF655 chr7 99558406 99576453 + DCAF12 chr9 34086387 34127399 - miRNA targets: NA circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC023509.1 chr12 53441741 53467528 + AC105942.1 chr1 94927361 94963616 + Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.